ReviewNature reviews. Neurology2022
Closing the loop for patients with Parkinson disease: where are we?
Review in Nature reviews. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Deep brain stimulation in PD: risk of complications, morbidity, and hospitalizations: a systematic review.Frontiers in aging neuroscience · 2023Pooled it
- Microneedle-Based Continuous Levodopa Monitoring in Patients with Parkinson's Disease.ACS sensors · 2026Article
- Improving multimodal wearable sensing for healthcare with artificial intelligence.Nature biotechnology · 2026Article
- Advances and Challenges in Wearable Sensors for Health Monitoring.ACS applied materials & interfaces · 2026Review
- Bilateral DLPFC transcranial direct current stimulation for mood and motor symptoms in Parkinson's disease: a preliminary study.Acta neuropsychiatrica · 2026Article
- Behavioral screening defines the molecular Parkinsonism-related subgroups in Drosophila.Nature communications · 2026Article
- A nanoMIP sensor for real-time in vivo monitoring of levodopa pharmacokinetics in precision Parkinson's therapy.Nature communications · 2025Article
- Smart closed-loop drug delivery systems.Nature reviews bioengineering · 2025Article
- Accelerometry is a valid method to distinguish between healthy and 6-OHDA-lesioned parkinsonian rats.Scientific reports · 2025Article
- Electrochemical Microneedles for Real-Time Monitoring in Interstitial Fluid: Emerging Technologies and Future Directions.Biosensors · 2025Review
- Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins.Scientific reports · 2025Article
- Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development.Micromachines · 2025Review
- Gut-brain axis modulation in remote rehabilitation of Parkinson's disease: reconstructing the fecal metabolome and nigral network connectivity.Frontiers in neurology · 2025Review
- An Interdisciplinary Approach to Assistive Technology for Parkinson's Disease Dementia.Clinical interventions in aging · 2025Review
- The Digitized Memory Clinic.Nature reviews. Neurology · 2024Review
- Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial.NPJ Parkinson's disease · 2024Article
- Levodopa: From Biological Significance to Continuous Monitoring.ACS sensors · 2024Review
- Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.Angewandte Chemie (International ed. in English) · 2024Article
- A decision support system based on recurrent neural networks to predict medication dosage for patients with Parkinson's disease.Scientific reports · 2024Article
- Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.Movement disorders : official journal of the Movement Disorder Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Although levodopa remains the most efficacious symptomatic therapy for Parkinson disease (PD), management of levodopa treatment during the advanced stages of the disease is extremely challenging. This difficulty is a result of levodopa's short half-life, a progressive narrowing of the therapeutic window, and major inter-patient and intra-patient variations in the dose-response relationship. Therefore, a suitable alternative to repeated oral administration of levodopa is being sought. Recent research efforts have focused on the development of novel levodopa delivery strategies and wearable physical sensors that track symptoms and disease progression. However, the need for methods to monitor the levels of levodopa present in the body in real time has been overlooked. Advances in chemical sensor technology mean that the development of wearable and mobile biosensors for continuous or frequent levodopa measurements is now possible. Such levodopa monitoring could help to deliver personalized and timely medication dosing to alleviate treatment-related fluctuations in the symptoms of PD. Therefore, with the aim of optimizing therapeutic management of PD and improving the quality of life of patients, we share our vision of a future closed-loop autonomous wearable 'sense-and-act' system. This system consists of a network of physical and chemical sensors coupled with a levodopa delivery device and is guided by effective big data fusion algorithms and machine learning methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.